We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

103 hedge funds and large institutions have $1.05B invested in Nurix Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 16 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 16

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

2% more funds holding

Funds holding: 101 → 103 (+2)

4.18% less ownership

Funds ownership: 93.29% → 89.11% (-4.2%)

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

18% less capital invested

Capital invested by funds: $1.28B → $1.05B (-$237M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $13K

Holders
103
Holders Change
+2
Holders Change %
+1.98%
% of All Funds
1.79%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.12%
New
17
Increased
52
Reduced
16
Closed
14
Calls
–
Puts
$13K
Net Calls
-$13K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$28.1M
2
ROTUOC
Regents of the University of California
California
+$16.8M
3
CS
Candriam SCA
Luxembourg
+$14.9M
4
State Street
State Street
Massachusetts
+$14.1M
5
Morgan Stanley
Morgan Stanley
New York
+$10.2M

Top Sellers

Rank Fund Capital Flow
1
CG
Column Group
California
-$167M
2
TGI
TRV GP III
Massachusetts
-$31.9M
3
RG
Redmile Group
California
-$3.64M
4
Nomura Holdings
Nomura Holdings
Japan
-$2.93M
5
PCM
Pinz Capital Management
New York
-$2.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
RSCM
26
Rock Springs Capital Management
Maryland
$8.37M +$129K +4,400 +1%
HMC
27
Harvard Management Company
Massachusetts
$8.35M – – –
DCM
28
DAFNA Capital Management
California
$8.13M – – –
Bessemer Group
29
Bessemer Group
New Jersey
$8.09M – – –
O
30
OrbiMed
New York
$7.96M – – –
Northern Trust
31
Northern Trust
Illinois
$7.88M +$1.89M +64,213 +28%
UBS AM
32
UBS AM
Illinois
$7.58M +$8.39M +285,880 New
Goldman Sachs
33
Goldman Sachs
New York
$7.45M -$1.94M -66,241 -19%
SFM
34
Sphera Funds Management
Israel
$6.48M +$854K +29,081 +14%
Ameriprise
35
Ameriprise
Minnesota
$5.96M +$149K +5,065 +2%
JRP
36
Jasper Ridge Partners
California
$4.79M +$4.32M +146,994 +439%
CCP
37
Clough Capital Partners
Massachusetts
$4.48M +$4.96M +168,800 New
EC
38
Euclidean Capital
New York
$4.1M +$4.53M +154,426 New
N
39
Nuveen
North Carolina
$3.95M +$255K +8,702 +6%
Charles Schwab
40
Charles Schwab
California
$3.45M +$498K +16,953 +15%
Citigroup
41
Citigroup
New York
$3.25M +$1.11M +37,755 +45%
Voloridge Investment Management
42
Voloridge Investment Management
Florida
$2.82M +$1.26M +42,968 +68%
TD Asset Management
43
TD Asset Management
Ontario, Canada
$2.12M +$18.2K +620 +0.9%
Rafferty Asset Management
44
Rafferty Asset Management
New York
$2.09M +$319K +10,863 +16%
Balyasny Asset Management
45
Balyasny Asset Management
Illinois
$2.08M +$1.03M +35,072 +81%
Bank of New York Mellon
46
Bank of New York Mellon
New York
$2.07M +$333K +11,329 +17%
Citadel Advisors
47
Citadel Advisors
Florida
$1.34M +$1.49M +50,671 New
HP
48
Harbourvest Partners
Massachusetts
$1.17M +$1.3M +44,141 New
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.17M +$561K +19,100 +77%
RJFSA
50
Raymond James Financial Services Advisors
Florida
$1.16M +$1.29M +43,826 New
1
2
3 4 5

NRIX Hedge Fund Activity: Q2 2021 in Review

103 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2021, worth a combined $1.05B — down 18% from $1.28B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new NRIX positions and 14 closed out — a net gain of 3 holders — while 52 added to existing stakes and 16 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $28.1M. The largest seller was Column Group, exiting entirely with an estimated $167M sold.

  • 103 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2021, up from 101 in Q1 2021.
  • Funds reported $1.05B of Nurix Therapeutics stock for Q2 2021, down 18% quarter-over-quarter.
  • 17 funds opened new Nurix Therapeutics positions in Q2 2021 and 14 closed out, a net change of +3 holders.
  • The largest Nurix Therapeutics buyer in Q2 2021 was T. Rowe Price Associates, an estimated $28.1M added.
  • The largest Nurix Therapeutics seller in Q2 2021 was Column Group, an estimated $167M sold.

Based on aggregated 13F filings for Q2 2021.